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Background: Rhesus (Rh) disease and extreme hyperbili-
rubinemia (EHB) result in neonatal mortality and long-term 
neurodevelopmental impairment, yet there are no estimates 
of their burden.
Methods: Systematic reviews and meta-analyses were 
undertaken of national prevalence, mortality, and kernicterus 
due to Rh disease and EHB. We applied a compartmental 
model to estimate neonatal survivors and impairment cases 
for 2010.
results: Twenty-four million (18% of 134 million live births 
≥32 wk gestational age from 184 countries; uncertainty range: 
23–26 million) were at risk for neonatal hyperbilirubinemia-
related adverse outcomes. Of these, 480,700 (0.36%) had either 
Rh disease (373,300; uncertainty range: 271,800–477,500) or 
developed EHB from other causes (107,400; uncertainty range: 
57,000–131,000), with a 24% risk for death (114,100; uncer-
tainty range: 59,700–172,000), 13% for kernicterus (75,400), 
and 11% for stillbirths. Three-quarters of mortality occurred in 
sub-Saharan Africa and South Asia. Kernicterus with Rh disease 
ranged from 38, 28, 28, and 25/100,000 live births for Eastern 
Europe/Central Asian, sub-Saharan African, South Asian, and 
Latin American regions, respectively. More than 83% of survi-
vors with kernicterus had one or more impairments.
conclusion: Failure to prevent Rh sensitization and man-
age neonatal hyperbilirubinemia results in 114,100 avoidable 
neonatal deaths and many children grow up with disabilities. 
Proven solutions remain underused, especially in low-income 
countries.
neonatal hyperbilirubinemia and jaundice occur in almost all newborns (1–10) and may be benign if its progression 
to extreme hyperbilirubinemia (EHB; total bilirubin (TB) 
>428 μmol/l in full-term babies) is recognized, monitored, 
and prevented or managed in a timely manner. Major risk fac-
tors include neonatal hemolysis (such as Rhesus (Rh) disease), 
glucose-6-phosphate dehydrogenase (G6PD) deficiency, infec-
tions, and an array of familial and genetic disorders. In addi-
tion to conditions such as preterm birth that make the neonate 
more susceptible to bilirubin neurotoxicity, suboptimal breast 
milk intake or dehydration may also contribute to EHB (1–10). 
At present, once the early stages of hyperbilirubinemic brain 
damage occur, therapeutic options are limited to the prompt 
(<8 h) use of exchange transfusion, hence the imperative for 
preventive approaches. Universal prenatal Rh screening for 
specific risk of perinatal hemolysis and its prophylaxis with Rh 
immunoglobulin have been highly effective practices for pre-
venting neonatal morbidities and mortality (11–14). Countries 
with universal access to perinatal health services have virtually 
eliminated severe hyperbilirubinemia (icterus gravis neona-
torum), which had been so common in the late 19th century 
(15–28).
Now with emerging affordable technologies, the world-
wide prevention and management of newborn jaundice can 
more feasibly reach those at risk even in low-income settings 
(1,2,29–31). Yet, there remains a paucity of quality population 
data on the prevalence of hyperbilirubinemia and related out-
comes to inform such a strategy for most countries (8).
In the absence of direct national or regional reporting, we 
report systematic estimates for the prevalence, mortality, and 
neurodevelopmental outcomes of Rh disease and EHB due 
to other causes, e.g., G6PD deficiency, prematurity, neonatal 
hemolysis, and idiopathic causes. We based these estimates, as 
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described below, on national risks of G6PD deficiency, preterm 
birth, neonatal hemolysis (not due to Rh disease), and other 
idiopathic causes, along with measures of the implementation 
gap for universal Rh prophylaxis.
Methods
Definitions and Measurements
Inconsistent use of definitions and management approaches limit the 
use of available data at both national and global levels. We used the 
following definitions shown in Figure 1, starting from perinatal risk 
factors, outcomes in terms of mortality, and then impairments (hear-
ing loss and neurodevelopmental impairment, including choreoath-
etoid cerebral palsy).
Rh disease or Rh hemolytic disease is defined by maternal–fetal Rh 
(D) antigen incompatibility and the consequences associated with 
maternal sensitization (see Web appendix I-iii for details and ref-
erences). This was the most common and severe cause of fetal and 
neonatal hemolysis in Europe and the United States until about 
60 y ago; it is now rare in countries where Rh prophylaxis is used. 
Women whose erythrocytes are Rh (D)-antigen negative are sensi-
tized (develop anti-Rh (D) antibodies) during a previous pregnancy 
in which the fetus is Rh (D)-positive or by exposure to Rh antigens 
from blood products/transfusion. Severe hemolytic disease mani-
fests in utero as progressive anemia and hypoalbuminemia, leading 
to anasarca (edema) and heart failure (hydrops fetalis), resulting in 
stillbirths or early neonatal deaths. Surviving infants can present with 
severe jaundice, anemia, and death from kernicterus or brain damage 
resulting from EHB. These complications can be treated with timely 
exchange blood transfusions. In most high-income countries, Rh dis-
ease has been eradicated by coordinated obstetrical and neonatal care 
(32). These prenatal interventions require expert assessment, use of 
Rh immunoprophylaxis, and diagnosis of fetal anemia, early signs of 
cardiac failure, or hydrops, in addition to the timely use of intrauter-
ine transfusion to correct hemolytic anemia.
G6PD deficiency is an X-linked inherited enzymopathy (33–40). 
G6PD deficiency is widespread (450 million people). There are vari-
able data regarding the distribution of individuals at risk for neonatal 
hemolytic crisis due to G6PD deficiency, partly due to diverse assay 
methods for enzyme activity or genetic identification and timing of 
the assay in relation to postnatal and chronological ages. Recent popu-
lation migration, sample size, and validity of the surveys also limit the 
accurate representation of a national prevalence (34). Existing pub-
lished data highlight important limitations due to the use of summa-
rized national levels that can mask subnational variations. Accurate 
(phenotypic) quantitative identification of deficient G6PD enzyme 
activity by spectrophotometry is a measure of the condition soon 
after birth. However, variations due to both partial phenotypic mani-
festations of diverse genetic mutations and the high enzyme activity 
of younger red blood cells are significant confounding factors. DNA/
polymerase chain reaction screening for specific mutations is ideal 
to identify female heterozygotes, but this approach is limited by the 
diversity of known variants and the occasional mismatch with pheno-
typic expression of enzyme activity. More recently, Luzzatto et al. (37). 
have suggested estimation of G6PD deficiency allele frequency to pre-
dict and generate population-weighted estimates of affected popula-
tion. Howes et al. (33). have used this approach to propose a Bayesian 
geostatistical model adapted to the gene’s X-linked inheritance that 
circumvents the above-mentioned limitations to assess national prev-
alence. There is paucity of data to estimate a neonate’s risk for G6PD 
deficiency following exposure to aggravating triggers that may cause 
unpredictable adverse consequences (35).
Prematurity: Preterm birth is any birth before 37 completed wk of 
gestation (<259 d since the first day of the woman’s last menstrual 
period) (41,42). Further subdivisions based on completed GA are 
as follows: late preterm (34 to <37 wk); moderately preterm (32 to 
<34 wk); and very preterm (<32 wk). The incidence of kernicterus in 
1955, i.e., before the clinical use of phototherapy, was 10.1, 5.7, 3.2, 
1.1, and 0.8% for infants at 30, 31–32, 33–34, 35–36, and >36 wk GA, 
respectively (43). We limited our analysis to the group of preterm 
births of >32 wk GA because preterm births <32 wk handle hyperbili-
rubinemia differently, and according to International Classification of 
Diseases rules, deaths and disability in this group should be allocated 
to preterm birth as the primary condition to address, so we will not 
include these here to avoid double counting the burden along with 
those included in preterm birth direct complications.
Clinical State and Outcome Definitions
EHB is defined as total plasma/serum bilirubin >25 mg/dl (428 
µmol/l) or those treated with exchange blood transfusion (44). 
Kernicterus or CBE has been used as a clinical diagnosis that relies 
on a history of excessive prolonged hyperbilirubinemia and classical 
abnormalities of muscle tone, movement disorders, and aberrant pro-
cessing disorders (26,45,46). Acute signs of extrapyramidal dysfunc-
tion may precede CBE. Acute bilirubin encephalopathy (31) includes 
progressive changes in an infant’s mental (behavioral) status, muscle 
tone, and distinct cry patterns. Acute clinical signs, initially described 
in 1955 by Crosse et al. (43), are as follows: “the first 24 to 48 hours of 
life are the most critical. Signs develop in a baby who is jaundiced… 
and include head retraction, an expressionless facies, usually with 
oculogyric movements, changes in muscle tone, cyanotic attacks, 
refusal to suck, vomiting and hemorrhage prior to death. In severe 
cases these signs are self-evident but in those less affected they are eas-
ily missed …. unless specifically sought.” “Several babies who showed 
minimal signs have proved to be definite cases of kernicterus.” Thus, 
neonatal mortality is due to respiratory failure and progressive coma 
or intractable seizures. An increased signal on magnetic resonance 
imaging of the globus pallidus and other areas prone to bilirubin neu-
rotoxicity is often evidenced in surviving infants. Posticteric clinical 
sequelae include irreversible, but static, classic signs of athetoid cere-
bral palsy, generalized dystonia, paralysis of upward gaze, “kernicteric 
facies,” and sensorineural hearing impairment. Neuromotor impair-
ment secondary to abnormal muscle tone includes dystonia that is 
characterized by excessive or sustained contraction of opposing 
muscles during voluntary movements, in addition to hypertonia or 
hypotonia. Painful muscle cramps, incoordination of sucking, swal-
lowing, and visuomotor function may manifest during early infancy. 
Cerebral palsy with choreoathetosis is another classic manifestation 
of kernicterus, which is characterized by involuntary movements or 
irregular muscle contractions that manifest as writhing or twisting. 
Paroxysmal movement disorders are often misdiagnosed and labeled 
as seizures. Hearing impairment is defined by sensorineural abnor-
malities ascertained by objective tests. Auditory system abnormalities 
with hyperbilirubinemia primarily involve brainstem nuclei, leading 
to abnormalities in auditory brainstem responses and detected by 
referred hearing screens during infancy. Auditory neuropathy, also 
called ‘‘auditory dyssynchrony,’’ is often subtler and associated with 
childhood hearing impairment (47–52). Developmental delay or cog-
nitive impairment, ascertained by the Bayley Mental Developmental 
Index, provides continuous variables to define the extent of aberra-
tions for mental and psychomotor indexes. In addition, infants’ intel-
ligence can be estimated or tested for intelligence quotients of <70 
using the Wechsler Intelligence Score for Children (47). Cognitive 
impairment has been reported and possibly related to associated 
hearing impairment, neuromotor impairment, or, possibly due to 
social neglect. Other posticteric sequelae may result from subtle signs 
either with exposure to TB levels that are lower than EHB or following 
partial treatment of EHB. These “soft” perturbations of sensory pro-
cessing disorders have been described as the syndrome of bilirubin-
induced neurologic dysfunction or “BIND” (53) but are intentionally 
not included in this study due to the limited data and consensus in 
definitions found in the literature.
Data Searches for G6PD Deficiency and Preterm Birth, With 
Effects on Neonatal Mortality, EHB, and Kernicterus
Systematic reviews of the main electronic literature databases (Ovid 
Medline, Ovid Medline In-Process and Non-Indexed Citations, 
PubMed, Cinahl, Global Health, Scopus, and Popline) were under-
taken using a combination of medical subject heading and free text 
words. Search terms used were exchange blood transfusion, kernic-
terus/bilirubin encephalopathy, death (from jaundice), phototherapy, 
G6PD deficiency, ABO incompatibility, Rh incompatibility, admission/
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readmission (for jaundice), sequelae, impairment, and outcomes. 
Reference lists of all the relevant studies were scanned to further iden-
tify studies of interest. We excluded case reports, nonhuman studies, 
those that did not have the relevant population or age group, those 
that did not focus on the relevant condition (jaundice, hyperbilirubi-
nemia, and encephalopathy), and those that did not provide relevant 
primary data (e.g., for prevalence/risk). In addition, we conducted a 
retrospective review of the historic Rh disease literature, commencing 
from identification as a clinical disease to the period Rh disease was 
considered “conquered.” Pivotal studies, cited in Appendix I, allowed 
for estimation of mortality and disease among survivors. We also iden-
tified population-based studies before the use of phototherapy, which 
reported on the outcome of systematic use of phototherapy. Due to 
rapid improvement in the access to and quality of specialized/intensive 
newborn care in countries with low-mortality settings, for mortality, 
encephalopathy, and long-term impairment risk, we decided to focus 
on recent literature only and extracted data from studies with birth 
cohorts having median year of 2005 or later. Where sufficient data 
were available, standard meta-analysis techniques were used to obtain 
pooled estimates of the relevant parameter’s risk, which included 
EHB-related neonatal mortality and bilirubin encephalopathy (acute 
and/or chronic). Heterogeneity across studies was evaluated using I2 
and χ2 tests, and where evidence of heterogeneity was present (I2 > 70% 
or P < 0.05), a random-effects model was used.
Data Searches for Rh Disease
A systematic review of the published literature using PubMed was 
performed to establish the prevalence of Rh-negative blood groups by 
country for all countries with NMR >5. Countries with NMR <5 were 
presumed to have good Rh prophylaxis and strong health systems, 
with very low number of cases of Rh disease in these countries. Search 
terms included “rh, rh blood-group system” (medical subject head-
ing term), “Rhesus,” and “Blood group.” Reference lists of all the rel-
evant studies were scanned to further identify studies of interest and 
Web-based resources were searched using Internet search engines. 
For countries with no available data, the prevalence of Rh-negative 
blood groups was estimated using the regional median prevalence 
(Web appendix I-iii).
A further systematic review using PubMed (search terms included 
combinations of “Rhesus,” “rhesus disease,” “erythroblastosis fetalis,” 
“rhesus h(a)emolytic disease of the newborn,” “outcome,” “neonatal 
death,” and “stillbirth”) was undertaken to estimate the outcome of Rh 
disease in the absence of effective treatment and limited to primary 
studies published before 1960 and to reviews without date limitations.
Pooling of Data by Country Context and Access to Neonatal 
Services
Data were not available to estimate every parameter for every country. 
Hence, we sought to use pooled data from countries that are simi-
lar in their access to and quality of care as these are closely linked 
to outcomes. Outcomes of EHB depend on a systematic approach 
to prevention and management of hyperbilirubinemia. We grouped 
countries into three NMR bands (NMR/1,000 live births) as follows: 
Group 1 (NMR <5), Group 2 (NMR 5 to <15), and Group 3 (NMR 
≥15), which approximate to high-, middle-, and low-income coun-
tries, respectively. Where data were available, we sought to further 
distinguish the outcomes between those with access to specialized 
neonatal care if required (including phototherapy and exchange 
blood transfusion) and those with basic/limited care only at home or 
in a facility with no access to these specialized services because this 
will affect the mortality and kernicterus outcomes.
Modeling Approach
A three-step compartmental model was constructed for each country 
with at least 10,000 live births for the year 2010 (54,55) as follows: Step 
1) estimation of the number of cases based on the prevalence of G6PD 
deficiency, late-preterm birth, and other causes of EHB, not due to Rh 
disease, in addition to estimating the prevalence of Rh disease; Step 2) 
estimation of the number of stillbirths, neonatal deaths, and cases of 
kernicterus by applying the risk data to the estimated cases; and Step 3) 
estimation of the numbers of survivors with neurodevelopmental 
impairment (Figure 2). All results are presented by regional grouping 
according to the Global Burden of Disease Study Group superregions 
Figure 1.  Schematic representation of the prenatal and neonatal risk factors for Rhesus (Rh) disease and extreme hyperbilirubinemia and their impact on still-
births, neonatal death due to kernicterus, and long-term impairment of kernicterus during childhood. In view of the complex confluence of biological risk, inter-
action with other childhood disease, and social–cultural factors, we did not estimate childhood death due to kernicterus. ABE, acute bilirubin encephalophathy.
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(56,57) (Appendix II). We quantified the uncertainty surrounding 
these estimates by taking 1,000 random draws of the input parameters 
at each step, assuming a normal distribution with mean equal to the 
point estimate of the parameter and SD equal to the estimated SE of 
the parameter (55). We summed the data at the worldwide or regional 
level for each draw and present the 2.5th and 97.5th percentiles of the 
resulting distributions as the uncertainty range.
results
We identified 23,145 relevant titles for the non-Rh disease causes 
of EHB. Of these, 2,599 abstracts and 185 pertinent publications 
were selected for full text review. Sixty-two studies (from 30 
countries) were screened; 26 met the criteria to provide popula-
tion source for occurrence of kernicterus (acute and/or chronic) 
and/or kernicterus-associated neonatal mortality (Web  appendix 
I-vii). We used the observational cohort of 41,324 infants born 
without Rh disease who were recruited for a multicenter study in 
the United States in 1959–1975 (58). Extrapolation of these data 
to the 134 million live births yielded the result that 1.1 million 
(0.8%) worldwide would develop TB >20 mg/dl (342 µmol/l), 
214,400 would progress to TB >25 mg/dl (428 µmol/l), and a 
total of 1,648,200 newborns would undergo exchange transfu-
sions. Studies excluded because of reported implementation of 
routine bilirubin screening showed that prophylactic use of pho-
totherapy in 6.6 ± 1.3% (95% confidence interval (CI): 4.4, 8.7) 
of live births >34 wk gestational age (GA) (3,59–61) drastically 
reduced the need for exchange transfusions.
Step 1: Estimation of Prevalence
Rh hemolytic disease prevalence. Postpartum Rh immuno-
globulin administration has been standard therapy for many 
years in high-income countries and Rh hemolytic disease has 
been virtually eradicated. Countries with a neonatal mortal-
ity rate (NMR) <5 were therefore presumed to have good Rh 
prophylaxis and strong health systems, with very few cases of 
Rh disease. It is likely that there are lapses in universal immu-
noprophylaxis in some of these countries. However, there are 
inadequate data to estimate the number of protection failures 
and the numbers would be small in the global perspective; 
therefore, our focus was on countries with an NMR >5.
Process: The prevalence of Rh-negative blood group was esti-
mated by country (see Methods and Web appendix I-iii) and 
the total births for 2010 were calculated as the sum of live births 
(54) and stillbirths (estimated assuming no change in stillbirth 
rates from 2009 to 2010) (62). These were used to estimate the 
total number of pregnancies in Rh-negative women in 2010. 
The number of Rh-positive babies born to those women was 
calculated knowing the Rh positivity prevalence in the fathers 
(i.e., the prevalence of Rh positivity in the country). For an 
Rh-positive baby to be born to an Rh-negative mother, it must 
receive at least one Rh allele (positive) from an Rh-positive 
father. The number of Rh-positive pregnancies represents the 
number of women who should have received Rh immunoglob-
ulin prophylaxis postpartum. The number of women who did 
Figure 2.  Schematic representation of the three-compartmental model. This model delineates the serial steps toward input of country-specific param-
eters, processes, and outputs to estimate prevalence, burden of Rhesus (Rh) disease and extreme hyperbilirubinemia–related mortality, and the number 
of postneonatal survivors with kernicterus and long-term impairment. A/CBE, acute/chronic bilirubin encephalophathy.
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receive prophylaxis is based on information on the worldwide 
distribution of Rh immunoglobulin preparations, obtained 
through the courtesy of The Marketing Research Bureau 
(http://marketingresearchbureau.com/; Orange, CT), which 
has tracked the plasma markets since 1974 through interviews 
with public organizations and private firms, governmental and 
nongovernmental organizations, trade associations, patient 
groups, and opinion leaders. Thus, we determined the num-
ber of women who did not receive postpartum protection. Of 
those unprotected women, it was previously calculated that 
15% would develop Rh isoimmunization and their anti-Rh 
antibodies would enter the circulation of their next baby (11). 
We calculated the risk of a second baby being Rh positive from 
the prevalence of the Rh positivity of the father. This risk fac-
tor was modified because the fathers in the second pregnancy 
do not account for the Rh-negative men who could have been 
fathers in the first pregnancy.
These serial calculations required several assumptions, lim-
iting their absolute accuracy. As will be noted, this results—for 
the most part—in an underestimation of the severity of the bur-
den. First, all calculations are based on two Rh-positive preg-
nancies; however, in many countries, the fertility rate (average 
number of babies per woman) is as high as 7.0; in Nigeria, e.g., 
in 2010, it was 4.9. With each successive Rh-positive pregnancy, 
the prevalence of Rh immunization increases. Prevalence data 
for Rh negativity were not available for all countries and within 
countries too, they varied. Accordingly, regional median esti-
mates were applied. Second, it is likely that in many countries 
where Rh immunoglobulin is available, there are many fail-
ures of protection. Our calculations are based on the assump-
tion that all the Rh immunoglobulin distributed in a country 
was used postpartum. That means that none was used during 
pregnancy or posttermination of pregnancy/miscarriage or 
for other medical indications and that each vial was used as 
a single dose and not divided for multiple recipients. Last, we 
have not included in our calculations that blood type A, B, O 
incompatibility reduces the likelihood of Rh isoimmunization 
(Table 1).
Outcome: In 2010, an estimated 373,300 babies were 
affected with Rh hemolytic disease worldwide. Data inputs are 
detailed descriptions by country in the Web appendix I-iv. The 
global estimated prevalence for Rh disease was 276/100,000 
live births. Prevalence for specific regions such as Southeast 
Asia/Pacific countries, Latin America, North Africa/the 
Middle East, South Asia, sub-Saharan Africa, and Eastern 
Europe/Central Asia is estimated at 57, 252, 278, 385, 386, and 
529/100,000 live births, respectively. These data are in contrast 
to Rh disease prevalence of 2.5/100,000 live births in coun-
tries that have well-established health-care infrastructure that 
includes coordinated perinatal–neonatal care for virtually all 
pregnancies.
Prevalence of Risk Factors for EHB
G6PD deficiency prevalence. Process: Country-specific preva-
lence for overall G6PD deficiency was obtained from (i) a geo-
statistical model reported for 97 endemic malaria countries (33); 
(ii) pooled estimates of ≥3 studies for each of these six countries 
(Croatia, Cyprus, Greece, Italy, Spain, and the United States) 
and the studies had used diverse methodologies to assay G6PD 
deficiency; (iii) regional estimates from Nkhoma et al. for the 
remaining 81 countries (33,34) (Table 2, Web appendix I-ii). 
Howes et al. (33) have provided the most recent report, a con-
tinuous evidence-based prevalence and estimate of the affected 
population that represents a national risk for countries endemic 
to malaria. Unlike the Nkhoma report (34), the G6PD deficiency 
phenotype was identified and then used to model the genotype 
for these countries (35). Prevalence was generally lower across 
Central and Southeast Asia compared with that in sub-Saharan 
Africa (usually <20%) but accounted for >60% of the affected 
general population.
Moderate- and late-preterm birth (32 to <37 wk gestational 
age) prevalence. Process: Prevalence of preterm birth rates 
by country was obtained from the data reported by Blencowe 
et al. (41). The study estimated that 84% of all preterm births 
occurred after 32 completed wk of gestation.
Estimation of risk for nonpreterm neonates without G6PD 
deficiency or Rh disease. Process: The population at risk of 
EHB but without any of the three quantified EHB risk factors 
table 1. Summary of input data on the prevalence of Rh disease, 
Rh disease–associated mortality, and bilirubin encephalopathy 
(kernicterus) 
Summary of input data on the prevalence of Rhesus disease for countries 
with NMR >5a (all calculations are based on two pregnancies per 
Rh-positive woman; see Web appendix I-iii)
Step 1 Country prevalence of Rh negativity
 Data from 55/138 countries
  Estimate based on regional medians for countries with 
no data
  An estimated 6.24 million births to Rh-negative women in 
these countries
Coverage of maternal anti-Rh (anti-D) immunoprophylaxis
 Data available from 43 countries
  For countries with no data available, it was assumed that 
no Rh prophylaxis was available.
Risk of Rh isoimmunization in pregnant women without 
prophylaxis (11)
 15.0% (uncertainty range: 13.3–19.1%)
Outcome of pregnancies affected by Rh diseaseb
Step 2 Stillbirths (23): 13.9% (95% CI: 12.6–15.3%)
Neonatal deaths (16): 23.8% (95% CI: 14.5–36.6%)
Survivors with kernicterus (20,23): 7.2% (95% CI: 3.8–11.2%)
CI, confidence interval; NICU, neonatal intensive care unit; NMR, neonatal mortality rate; 
Rh, Rhesus.
aAssuming universal availability of comprehensive pre- and postnatal treatment to 
prevent adverse outcomes in those with failure of anti-D immunoprophylaxis in 46 
countries with NMR <5, estimates were undertaken only for remaining countries. 
bAssuming no availability of pre- or postnatal treatment such as intrauterine 
monitoring, correction of anemia, exchange blood transfusion, or phototherapy for 
progressive hyperbilirubinemia.
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table 2.  Summary of input data on the prevalence of risk factors, risk of EHB, neonatal mortality, and kernicterus in 2010 by NMR levels for non-
Rh-related EHB 
Groupings
Countries according to NMR levels in 2010
NMR <5 NMR 5 to <15 NMR ≥15
184 countries 46 63 75
Live births 13 million 41 million 80 million
Step 1 Birth prevalence for specific risk factors
  Input data: geostatistical model estimates (Howes et al. (33)) from 89 countries and regional pooled estimates  
(Nkhoma et al. (34)) from 95 countries (see Web appendix I-ii).
 Input data for preterm birth estimates from “Born Too Soon” (41)
30 countries 28 countries 41 countries
415 data sets 187 data sets 136 data sets
Preterm births Preterm births Preterm births
Sample = 11.0 million Sample = 5.2 million Sample = 1.9 million
Median: 6.8% Median: 5.9% Median: 8.5%
Range: 4.1–16.4% Range: 3.1–19.5% Range: 3.5–28.5%
Gestational age subdivisions: 345 data points
32–36 wk: 84.3% (95% CI: 84.1–84.5%)
Risk of EHB
 In term babies without G6PD deficiency or Rh disease:
  1 Country, 1 data set (Canada: phototherapy used to prevent EHB in widespread use)
  n (babies with no risk factor) = 582,592
  Risk = 0.038% (95% CI: 0.033–0.043%)
  Increased risk in babies without access to phototherapy to prevent EHB (59)
  Increased risk = 2.45 (95% CI: 1.44–4.16)
  Overall risk = 2.45 × 0.038% = 0.093% (uncertainty range: 0.033–0.163%)
 In babies with G6PD deficiency
  1 Country; 1 data set
  n (G6PD-deficient babies) = 15,168
  Risk = 0.132% (95% CI: 0.085–0.20%)
  (Relative risk = 3.5)
  Increased risk in babies without access to phototherapy to prevent EHB (59)
  Increased risk = 2.45 (95% CI: 1.44–4.16)
  Overall risk = 2.45 × 0.132% = 0.323% (uncertainty range: 0.082–0.669%)
 In preterm births (32 to <37 wk)
  1 Country; 1data set
  n (preterm births) = 42,240
  Risk = 0.045% (95% CI: 0.029–0.070%)
  (Relative risk = 1.20)
  Increased risk in babies without access to phototherapy to prevent EHB (58)
  Increased risk = 2.45 (95% CI: 1.44–4.16)
  Overall risk = 2.45 × 0.045% = 0.110% (uncertainty range: 0.025–0.231%)
Step 2 Risk of mortality in infants with EHB with access to treatment
3 studies 2 studies 16 studies
n (deaths) = 8 n (deaths) = 10 n (deaths) = 144
Pooled mortality risk: 2.4%  
(95% CI: 0–5.8%)
Pooled mortality risk: 8.2%  
(95% CI: 3.3–13.1%)
Pooled mortality risk: 16%  
(95% CI: 10.2–21.9%)
Risk of mortality in infants with EHB with no access to treatment
Not applicable 1 study, United Kingdom, 1952 (19)
n (deaths) = 18
Mortality risk: 31.6% (95% CI: 21.0–44.5%)
Risk of kernicterus in EHB survivors with access to treatment
6 studies 6 studies 15 studies
n (survivors with kernicterus) = 1,498 n (survivors with kernicterus) = 134 n (survivors with kernicterus) = 366
Pooled risk: 23.0% (95% CI: 9.9–36.1%) Pooled risk: 35.0% (95% CI: 12.0–58.0%) Pooled risk: 43.8% (95% CI: 25.5–62.1%)
Risk of kernicterus in EHB survivors with no access to treatment
Not applicable 1 study, United States, 1950s (20)
Risk: 50.0%
Uncertainty range: 36.1–63.9%
CI, confidence interval; EHB, extreme hyperbilirubinemia; NMR, neonatal mortality rate.
Copyright © 2013 International Pediatric Research Foundation, Inc.  Volume 74  |  Number s1  |  December 2013      Pediatric RESEARCH 91
Articles         Bhutani et al.
(G6PD deficiency, Rh disease, or prematurity) was obtained 
mathematically by subtracting the sum of the live births with 
each risk factor from the total population of live births. This 
subgroup includes infants with risk of undifferentiated, but 
major, causes of EHB: neonatal hemolysis (including ABO 
incompatibility and other red blood cell disorders) and an 
increasingly recognized array of idiopathic causes (Table 2).
Risk of EHB. Process: Two sets of population studies from 
Canada and Denmark (63–69) provided data on the num-
ber who develop EHB and listed causes for EHB (excluding 
Rh disease because of effective national Rh prophylaxis pro-
grams). We requested Sgro and Ebbesen to provide additional 
unpublished data to clarify the prevalence for G6PD deficiency 
and preterm births in a comparable EHB cohort. We relied on 
the Canadian data (66–68) to inform prevalence data estimate 
because the population and causes of jaundice were more 
heterogeneous than that in the Danish data (63–65,69). The 
combined Canadian and Danish data set includes unpublished 
data on outcomes at age >2 y and EHB data for preterm neo-
nates. In the absence of data from other settings, the same risk 
was applied to all countries. As these studies were undertaken 
in populations with low rates of infection and intrauterine 
growth restriction, with access to full prenatal screening and 
comprehensive neonatal care including prophylactic interven-
tions with phototherapy and/or exchange blood transfusion, 
the risk of EHB is likely to be lower than that in settings without 
such access. In particular, for the “global” preterm baby, much 
of the increased risk of EHB is due to its increased infection 
vulnerability. In this supplement, to avoid double counting 
the long-term impairment in these babies, this burden has 
been included under infection (70). We sought to adjust for 
the effect of access to phototherapy and the risk of EHB using 
data for babies of >2 kg weight from a trial of phototherapy 
to reduce hyperbilirubinemia, where babies without access to 
phototherapy had 2.45 times the risk of developing EHB (58).
From the Canadian data, we estimated the global risk of EHB 
without any of the three risk factors and assuming an average 
2.37% G6PD prevalence reported in military recruits in the 
United States (36) and extrapolated it to the Canadian data; 
we calculated the risk of EHB in G6PD-deficient babies to be 
0.13%, as shown in Table 3. To estimate the EHB prevalence 
due to G6PD deficiency, we assumed an equivalent biological 
risk across the different countries and regions and applied this 
risk to the prevalence of G6PD deficiency in each country to 
calculate the population of G6PD-deficient babies who would 
develop EHB.
The Canadian population–based study also reported 19 cases 
of EHB in preterm babies 34 to <37 wk gestation (66–68). This 
gives a EHB risk of 0.045%, assuming that 6.6% of live births 
are late preterm in Canada (Table 3). This presents a likely 
underestimation of the risk because of the following: (i) pre-
cise definitions for EHB are not available for preterm infants 
and bilirubin-associated neurological damage is likely to occur 
table 3.  Outcome of acute kernicterus (bilirubin encephalopathy) in two high-income countries 
Canada Denmark Combined
Study period 2007–2008 2000–2007 —
Number of live births 740,000 502,766 (GA ≥35 wk) 1,242,766
Total cases of kernicterus (total prevalence per live birth) 20 3 23  
(1.8/100,000)
Peak TB Mean: 568 μmol/l 651,734,986 μmol/l 429–986 μmol/l
Peak TB range 429–795 μmol/l
Presenting with acute kernicterus (prevalence/live births) 14 3 severea 17 (74%)  
(1.4/100,000)
Developmental follow-upb
 Hearing impairment (abnormal ABR) 14/17 3/3 17/20 (85%)  
(95% CI: 64.0–94.8%)
 Abnormal MRI 16/18 1/3 17/21 (81%)
 Follow-up at ≥2 y of age 14 3 17/23 (74%)
 Developmental delay 11 3 14/17 (82.4%)  
(95% CI: 59.0–93.8%)
 Choreoathetosis or dystonia (cerebral palsy) 5 3 8/17 (47.1%)  
(95% CI: 26.1–69.0% )
 Normal development 3 0 3/17 (17.7%)  
(95% CI: 6.2–41.0%)
 Other neurodevelopmental issues 4 0 4/17 (23.5%)  
(95% CI: 9.6–47.3%)
Data are provided, courtesy of Michael Sgro and Finn Ebbesen (63–68), who searched their databases that have previously been reported, and complemented with additional 
information as shown above (see Web appendix I-vi for details).
ABR, auditory brainstem response; GA, gestational age; TB, total serum/plasma bilirubin.
aTwo other milder cases were reversible. bIncludes those with known outcome only.
92 Pediatric RESEARCH     Volume 74 | Number s1 | December 2013  Copyright © 2013 International Pediatric Research Foundation, Inc.
Beyond survival: burden of kernicterus         Articles
at lower levels than in term babies; and (ii) because there were 
no surveillance data to quantify the risk of EHB in premature 
babies GA 32 to <34 wk, we assumed the risk to be the same as 
in those of GA 34 to <37 wk.
EHB outcome: Globally, we estimated that of the 11 mil-
lion (uncertainty range: 11–12 million) babies born at risk for 
G6PD deficiency, an estimated 27,000 cases of EHB occurred 
in G6PD-deficient babies. Latin America, South Asia, and 
sub-Saharan Africa account for 2, 33, and 47% of the G6PD-
deficient infants with EHB, respectively, for a combined 
prevalence of 28/100,000 live births. This is in contrast with 
 high-income nations that account for 2.2% of global burden of 
EHB due to G6PD deficiency, with a prevalence of 5/100,000 
live births.
We estimated that of the 13 million (uncertainty range: 12–
14 million) babies born at GA 32–37 wk, at least 10,000 devel-
oped EHB. Latin America, sub-Saharan Africa, and South Asia 
account for 4, 32, and 39% of the EHB cases, respectively, for a 
combined prevalence of 10/100,000 live births. This is in con-
trast with high-income nations where the 4% moderate and 
late-preterm live births have an EHB prevalence of 3.5/100,000 
live births.
We estimated that of the remaining 111 million babies born 
at GA >36 wk, at least 70, 000 developed EHB that would be 
attributed to undifferentiated causes but we combined occur-
rence of EHB due to neonatal hemolytic and/or idiopathic 
conditions, but unrelated to Rh disease.
Global prevalence of EHB and Rh disease. We estimated 
that 373,300 live births (uncertainty range: 271,800–477,500) 
in 2010 were affected by Rh disease (277/100,000 live births; 
Table 4) and 107,400 live births by EHB due to other causes: 
10% moderate and late preterm (8/100,000 live births); 25% 
G6PD (20/100,000 live births); and 66% due to other hemo-
lysis/idiopathic causes. The majority of the total EHB and Rh 
disease (80%) occurred in those born in countries with NMR 
>15 that account for 60% of the global live births.
Step 2: Estimation of Postneonatal Survivors From Rh Disease 
and EHB
Rh disease–related mortality and kernicterus. Process: It was 
assumed that infants born with Rh disease without the ben-
efit of prenatal screening and coordinated Rh prophylaxis and 
intensive treatment (such as serial middle cerebral velocity 
measurements, recognition and correction of fetal anemia, 
timing for safe birthing, and postnatal treatment with exchange 
transfusion or phototherapy) would have an outcome similar 
to that reported by investigators before the 1950s (before the 
availability of exchange blood transfusion and phototherapy) 
for neonatal mortality and before 1970 for stillbirth outcomes 
(Web appendix I-v).
Walker described a large series of newborns with Rh 
disease and reported the stillbirth rate at 14% (23). This is 
consistent with a smaller study where 13% of noninduced 
pregnancies affected with Rh disease were stillborn (19). 
The reported neonatal mortality in live births affected by Rh 
disease was 32% (24/75) in a series from the United States 
during the period 1928–1945 (15), which is consistent with 
the results in other retrieved studies (Web appendix I-v). As 
noted by Vaughan in 1950 (16), these results are not com-
parable because the population denominator included only 
clinical cases before the advent of serological testing in the 
early 1940s and because the numerator frequently included 
the composite measure of adverse outcome (kernicterus or 
death) and not death only. In view of these limitations, we 
used only the 1945–1946 data on live birth outcomes from 
the Boston Hospital (16), where the population denominator 
included all cases diagnosed serologically, including mild or 
subclinical cases, and where it was possible to estimate the 
mortality rate without including the kernicterus survivors. 
Because our outcome of interest was the risk of neonatal 
death out of all births in Rh-sensitized pregnancies (includ-
ing stillbirths), we adjusted the denominator (assuming the 
stillbirth rate in the population to be 14%, as above) and 
estimated that 24% of all Rh-immunized pregnancies would 
result in neonatal deaths.
In Walker’s large series of pregnancies affected with Rh 
disease, 33% of newborns required no treatment (23). 
We  have assumed that 14% of Rh disease pregnancies will 
result in stillbirths and 24% in neonatal deaths and that the 
remaining 29%, who require treatment, will have severe 
hyperbilirubinemia. Hsia et al. (20) reported that 50% of 
untreated infants whose peak TB reached >513 μmol/l 
(30 mg/dl) developed kernicterus, consistent with observa-
tions made by Mollison and Walker (19). We assumed that 
50% of babies with Rh disease and hyperbilirubinemia would 
reach a level greater than 30 mg/dl (513 µmol/l) in keeping 
with the clear indication for exchange transfusion for babies 
with Rh disease (as described by Walker) to prevent kernic-
terus. Overall, we estimated 7.2% of all Rh disease–affected 
table 4.  Estimated cases of Rh disease and EHB due to other causes grouped by country NMR levels 
NMR group (per 1,000 live births)
Moderate and 
late preterm
G6PD 
deficiency
None of 
three risk 
factors
EHB (non-
Rh disease)
EHB uncertainty 
range: low to high Rh disease
Rh disease 
uncertainty 
range: low to high
<5 500 700 4,400 5,600 4,800–6,600 0
5 to <15 1,600 3,000 16,200 20,800 16,500–23,400 69,600 50,700–89,000
≥15 8,100 23,100 49,800 81,000 34,800–102,700 303,600 221,000–388,000
Worldwide total 10,200 26,900 70,300 107, 400 57,000–131,000 373,300 271,800–477,500
EHB, extreme hyperbilirubinemia; G6PD, glucose-6-phosphate dehydrogenase; NMR, neonatal mortality rate; Rh, Rhesus.
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infants who survived had developed subsequent kernicterus 
(Table 1).
Non-Rh disease EHB mortality and kernicterus adjusted for 
access to neonatal care. Process: We estimated the number 
of babies with EHB and/or Rh disease who develop acute 
kernicterus or die in the neonatal period. The risk for acute 
(ABE) and chronic bilirubin encephalopathy (CBE; ker-
nicterus) was calculated together to avoid overreporting of 
cases because many articles had given figures for both with-
out specifying how many babies had both ABE and CBE. If 
individual data were listed for ABE and CBE (kernicterus), 
we chose the higher value for our analysis (Table 2 and Web 
appendix I-v).
Outcome in countries with “good” access to neonatal care 
(NMR <5): In these countries, almost all babies requiring care 
would have access to specialized facilities. The risk of bilirubin 
encephalopathy in this group was estimated from six relevant 
articles from four countries (71–75), and it included a large 
cohort study with 7-y follow-up from the United States (76). 
The pooled risk of encephalopathy was 23.0% (95% CI: 9.9, 
36.1). On the other hand, the pooled mortality data using two 
data sets specifically from the United States from among the 
three pooled data sets showed a bilirubin encephalopathy rate 
of 2.4% (95% CI: 1.0, 5.8).
Outcome in countries with “intermediate” access to neona-
tal care (NMR 5 to <15): In this group, the majority of the 
population would have access to neonatal intensive care unit 
(NICU) care, but the quality of care may be variable. A small 
proportion would have no access to NICU care or treatment. 
Pooling results from six studies conducted in NICU set-
tings yielded an encephalopathy risk of 35.0% (95% CI: 12.0, 
58.0) for those with access to NICU care, whereas the aver-
age NMR derived from two studies was 8.2% (95% CI: 3.3, 
13.1). For the small proportion of population with basic or 
no access to health care, risks of encephalopathy and neona-
tal mortality derived from the “marginal access” countries 
were applied.
Outcome countries with “limited” access to neonatal care: 
This group of countries has the largest and most heteroge-
neous population, with around 50 million home births with 
no care, facility births with some care, and a limited number 
of urban or richer families with variable access to NICU care. 
We used extensive work published elsewhere to estimate the 
access to care within these countries (55) (Web appendix II-ii). 
The neonatal kernicteric mortality for NICU care was esti-
mated by pooling results from 16 studies (eight countries) that 
included ten countries from Africa. The pooled mortality risk 
was 16.0% among infants with EHB (95% CI: 10.2, 21.9%). In 
those without any access to care, we conservatively selected a 
mortality of 35% based on a study conducted in the late 1940s, 
when treatment options were limited to exchange blood trans-
fusion at specialized centers. For the risk of encephalopathy at 
the NICU level, 15 facility-level data sets from seven countries 
were available, and the pooled estimate was 43.8% (95% CI: 
25.5, 62.1).
Global estimate of mortality associated with Rh disease and 
EHB due to other causes. There were 114,000 neonatal deaths 
associated with these conditions in 2010 (85/100,000 live births 
Figure 3.  Number of stillbirths (due to Rhesus (Rh) disease; white bars) and neonatal deaths/100,000 live births due to kernicterus (black bars) for all live 
births in 2010. These data are shown for regional geographic distribution. Regional categorization of countries is consistent with the global burden of 
diseases (54,55).
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(22% or 25,000 deaths with EHB, uncertainty range: 10,000–
36,000). There were 89,000 deaths (78%) associated with Rh 
disease (uncertainty range: 42,000–151,000). Eastern Europe/
Central Asia, Latin America, sub-Saharan Africa, and South 
Asia account for 6, 7, 35, and 39% of the deaths, respectively, 
for a combined prevalence of 119/100,000 live births compared 
with 0.1% (n = 94; prevalence 1/100,000 live births) in high-
income countries (Figure 3).
Global estimated risk of stillbirths due to RH disease. We 
estimated 52,000 stillbirths due to Rh disease (Figure 3). To 
investigate the contribution of EHB and/or fetal Rh disease, 
we relied on data reported from high-income countries from 
an era before universal Rh immunoprophylaxis. It is unusual 
for non-Rh disease EHB to present with fetal manifestations. 
Stillbirths are less likely in pregnancies at risk for EHB without 
Rh disease. However, we are underestimating both stillbirths 
and neonatal deaths for remote communities or nations in 
conflict.
Global estimates of number of babies with kernicterus. There 
were 75,400 cases (uncertainty range: 43,200–95,800) that 
represent 24% of the surviving 314,700 neonates with EHB 
and Rh disease who developed kernicterus, for a prevalence 
of 56/100,000 live births. Figure 4 illustrates the contributory 
causes of newborn jaundice that led to kernicterus. There were 
48,500 (64%) and 26,900 (36%) cases of kernicterus associ-
ated with non-Rh EHB and Rh disease, respectively. Eastern 
Europe/Central Asia, Latin America, sub-Saharan Africa, and 
South Asia account for 3.8, 5.8, 35, and 37% of the kernicterus 
cases, respectively, for a combined prevalence of 73/100,000 live 
births, compared with 1.6% (n = 1,193; prevalence 10/100,000 
live births) from high-income countries.
Step 3: Estimation of Impairment due to Kernicterus
Global estimate of survivors with NDI following kernicterus. 
The estimated risk of long-term impairment among survivors, 
globally, is shown in Figure 5. We based the risk on a recently 
published systematic review and data provided by Sgro and 
Ebbesen (63–68), which are more specific than those previ-
ously provided by Ip et al. (6). We assumed a constant biologic 
risk and applied this risk of impairment to all the survivors of 
kernicterus regardless of the level of care and mortality setting 
because the effect of bilirubin encephalopathy is not reversible (a 
global prevalence of 56/100,000 live births) and hence estimated 
the number of impaired survivors with long-term impairment 
according to specific global regions (Table 5 and Figure 6).
discussion
Our study is the first to provide global estimates of Rh dis-
ease and EHB, in addition to the resulting burden, in terms 
of deaths and impairment. Every year, ~24 million pregnan-
cies and their babies are at risk worldwide. The global burden 
of EHB and Rh disease is disproportionately heavy for the 
poorest countries: 11-fold higher for infants born in countries 
with NMR >15 compared with those with NMR <5 (384,600 
vs. 5,600 live births affected, with prevalence of 480 vs. 42 per 
100,000 live births). The outcomes are affected by lack of both 
preventive services and care (Figure 5).
Of the 480,700 live births at risk of Rh disease, 24% were at 
risk of neonatal death (114,100; uncertainty range: 59,700–
172,000), 13% at risk for kernicterus (75,400; uncertainty range: 
Figure 4.  Estimated rates of kernicterus (per 100,000 live births). Data are presented and attributed to cause of hyperbilirubinemia due to prematurity 
by yellow bars; G6PD deficiency by green; hemolytic and idiopathic conditions by blue; and Rhesus (Rh) disease by red. These are shown for regional 
geographic distribution worldwide using global burden of diseases (GBD) categorization (54,55).
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43,200–95,800), and 11% for stillbirths. Yet, knowledge of Rh 
disease has been iconic for more than 6 decades and means for 
its prevention have been established for more than 40 y. There 
has been an egregious failure to prevent Rh sensitization and its 
adverse consequences worldwide. The global “know–do” gap 
can only be bridged if nations assume their responsibility to 
address these disparities in maternal–child health care. Barriers 
include low attention to this issue, poor dissemination of evi-
dence-based tools for effective Rh disease prevention, and high 
cost for the currently available immunoprophylaxis. In addition, 
prevention and management of EHB is even more neglected.
Our study exposes the variations in risk, and hence national 
data are important for effective health service planning. 
Currently, these newborns are born into the following three 
very different worlds, reflecting a transition from high neo-
natal mortality to preventable disability in otherwise-healthy 
newborns:
1. Countries with higher NMR (≥15) are at the highest 
risk for neonatal mortality due to Rh disease and EHB. 
Here, reduction in Rh sensitization and better care of 
every newborn, including management of EHB when 
needed, is an urgent implementation priority. The 
challenge is to provide unfettered and affordable access 
to Rh immunoprophylaxis and reach those in remote 
regions or those dispersed in areas of conflict and post-
conflict settings.
2. Emerging countries with lower NMR (5 to <15) that 
exhibit variations in the quality of care, with vari-
able penetration of a systems approach for maternal 
and newborn care, including for Rh disease and EHB 
management. The management and prevention of 
Rh sensitization appears to have penetrated clinical 
practice, but it does not seem to be universal. On the 
other hand, EHB burden is vastly underestimated for 
preterm birth, G6PD deficiency, and unrecognized 
neonatal hemolysis. In addition, causes for underly-
ing neonatal mortality are erroneously labeled and 
not attributed to kernicterus, which leads to further 
underestimation of its disease burden. Here, there 
is an urgent need to strengthen neonatal screening 
and delivery services and to focus on the outcome of 
impairment-free survival.
Figure 5.  Outcomes for Rhesus (Rh) disease–affected pregnancies and 
extreme hyperbilirubinemia (without Rh disease). aStillbirths due to non-
Rh disease have not been estimated or included.
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table 5.  Global distribution of long-term impairment following kernicterus 
GBD region (live births)
Hearing 
loss (ABR) Low–high
Developmental 
delay Low–high
Athetoid 
cerebral 
palsy Low–high
Other 
neurological 
disability Low–high
Normal 
outcome Low–high
High-income countries 
(11,693,000)
1,000 (9) 500–
1,600
1,000 (8) 500–
1,600
600 (5) 200–
1,000
300 (2) 0–600 200 (2) 0–500
East, Southeast Asia 
and Pacific (29,021,000)
6,600 (23) 3,800–
8,700
6,400 (22) 3,600–
8,700
3,600 (12) 1,600–
5,600
1,800 (6) 0–3,600 1,400 (5) 0–3,100
Eastern Europe/ 
Central Asia (5,358,000)
2,500 (46) 1,400–
3,700
2,400 (45) 1,300–
3,700
1,400 (25) 600–
2,400
700 (13) 0–1,500 500 (10) 0–1,200
Latin America and 
Caribbean (9,855,000)
3,700 (38) 2,100–
5,300
3,600 (36) 2,100–
5,100
2,100 (21) 900–
3,400
1,000 (10) 0–2,200 800 (8) 0–1,800
North Africa and 
Middle East (9,665,000)
4,000 (42) 2,400–
5,200
3,900 (41) 2,300–
5,100
2,200 (23) 1,000–
3,500
1,100 (12) 0–2,200 800 (9) 0–1,900
South Asia  
(37,103,000)
23,900 (64) 12,200–
31,100
23,100 (62) 12,200–
30,500
13,200 (36) 5,200–
20,500
6,600 (18) 0–13,000 5,000 (13) 0–11,000
Sub-Saharan Africa 
(32,068,000)
22,500 (70) 11,700–
30,200
21,800 (68) 11,100–
29,400
12,400 (39) 5,100–
19,800
6,200 (19) 0–12,700 4,700 (15) 0–10,500
Worldwide total 
(134,762,000)
64,100 (48) 36,000–
83,300
62,100 (70) 35,200–
81,800
35,500 (26) 15,000–
155,500
17,700 (13) 0–36,000 13,300 (10) 0–29,000
All numbers rounded to the nearest 100. Parenthetical data in columns 2–10 represent prevalence per 100,000 live births. Data in italics represent uncertainty. Bolded data represent 
estimates of worldwide total.
ABR, auditory brainstem response; GBD, global burden of diseases.
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3. High-income countries, with NMR <5, have achieved 
both a near elimination of neonatal mortality associ-
ated with kernicterus and reductions in impairment. 
Here, a better identification of postnatal hemolysis and 
improved management of idiopathic etiologies remain 
as challenges.
Our estimates suggest that Rh disease accounts for the 
majority of the total global EHB burden (uncertainty range: 
271,800–477,500). Although it should be underlined that our 
study vastly underestimates the burden of EHB because we 
excluded cases of extreme preterm birth (<32 wk GA) and 
those with infections to avoid double counting with the bur-
den estimates for those conditions because a neonatal death 
in a very preterm neonate or in one with severe infection and 
jaundice but no clear cause of hemolysis would be attributed to 
preterm birth or infections as a cause of death by International 
Classification of Diseases rules. In addition, given the lack of 
population-based risk data, we relied on estimates of risk from 
one low-mortality context in Canada for preterm birth, G6PD 
deficiency, and unrecognized neonatal hemolysis, including 
ABO incompatibility, which will be much lower than the real-
ity in many other countries (Table 2).
Estimates from high-income nations reveal benign out-
comes for most infants affected by Rh disease. For example, 
kernicterus mortality trends in the United States from 1979 
to 2006 used data from the US National Center for Health 
Statistics of 108,888,600 live births; the crude kernicterus 
death rate was estimated at 0.28 (95% CI: 0.25, 0.40) with a sig-
nificantly higher risk in males (28). In the same retrospective 
review of kernicterus among children born from 1988 to 1997 
in California, the time trend data estimated an incidence of 
0.44 cases (95% CI: 0.28, 0.65) per 100,000 annual live births. 
Incidence of EHB due to conditions other than Rh disease 
following systematic prevention of Rh disease in the United 
States, for 4 decades before 2004 was estimated at a preva-
lence of 169/100,000 live births (76) and has now declined to 
40/100,000 live births through implementation of a systems 
approach (71). Unlike in the United States, the Rh disease bur-
den remains extraordinarily high among countries with NMR 
≥5 and overshadows EHB due to other causes.
Lack of Unfettered Access to Neonatal Services and Risk of 
Impairment
The “screen and prevent approach,” which implements a sys-
tems approach, has started to transform the EHB burden, par-
ticularly in countries with NMR <10. The current prevalence 
of EHB-related mortality in nations with good access to neo-
natal services (>90% access to NICU) compared with those 
having marginal care (a combination of basic and NICU care) 
shows extraordinary disparity. Data availability and inconsis-
tent definitions varied, with the least data coming from the 
highest-burden settings. From a global perspective, we esti-
mate that among countries with NMR >15, infants with EHB 
were least likely to be admitted to a facility where they can 
receive the required specialized and coordinated perinatal-
NICU care. Overall, 46/100,000 live births (83% of survivors 
with kernicterus) were estimated to have long-term neurode-
velopmental impairment (Table 5). Our estimates of 36,000 
cases of cerebral palsy (uncertainty range: 15,000–55,000) 
globally is undoubtedly an underestimate because of our 
reliance on the Canadian data for risk of impairment, apart 
from the exclusion of those with extreme preterm birth and 
infections. Indeed, a newborn who is preterm, with infection 
Figure 6.  Number of infants with major impairments due to kernicterus as presented for hearing loss (white bars) and athetoid cerebral palsy (black 
bars). Data shown for all live births in 2010 are shown for regional geographic distribution. Regional categorization of countries is consistent with the 
global burden of diseases (54,55).
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and jaundice, is at the highest risk of impairment (77). Here, 
South Asia and sub-Saharan Africa were estimated at 26,000 
(37/100,000) vs. 560 cases (5/100,000 live births) from high-
income countries (approximately an eightfold higher bur-
den). Low coverage and the quality of pre- and postnatal 
coordination for “health  services” is specifically exemplified 
by the  ineffective Rh immunoprophylaxis in low- and middle-
income countries. The transition of health services in certain 
Eastern Europe/Central Asian countries illustrates the high 
prevalence of Rh sensitization, but a much lower prevalence 
of Rh disease adverse outcomes, compared with the situation 
in South Asia and sub-Saharan Africa.
Data Limitations
Presently, no single replicable test exists to further measure 
the risks for EHB. Hence, we sought to estimate burden as 
conservatively as possible, including ABO incompatibility in 
other causes of EHB because ABO hemolytic disease alone 
has not been shown to cause neonatal death (1,6,8,27). A 
recent retrospective review suggests a statistically significant 
interaction between a positive Coombs test, EHB, and lower 
intelligence quotient during childhood (61), but more popu-
lation-based data are needed to define the magnitude of this 
risk. G6PD deficiency prevalence data are limited, especially 
regarding defined enzyme level activity adjusted for gender. 
Adverse exacerbations by exposures to drugs, toxins, infec-
tions, and dietary agents add to the unpredictable risk of 
EHB due to G6PD deficiency (35) and are underestimated 
in our study due to reliance on the risk data from Canada 
alone. The EHB risk among late and moderate preterm birth 
we applied was minimal (about 5% or less) because we used 
a very high bilirubin threshold to define EHB and the risk 
from the Danish and Canadian data, which are in the con-
text of very high–capacity neonatal care. Adjustment for 
risk for developing bilirubin neurotoxicity among preterm 
infants is more complex (2). Thus, we believe that we have 
significantly underestimated the prevalence of neonatal 
hemolysis, G6PD deficiency, and prematurity-related EHB. 
Similarly, race and ethnicity often affect bilirubin elimina-
tion disorders due to an array of genetic conditions masking 
as idiopathic factors (1,2). In developing nations, vulner-
ability to EHB continues to be confounded by comorbidi-
ties that include sepsis, intrauterine growth restriction, and 
unscreened inborn errors. We also did not study infants who 
received an exchange blood transfusion at lower TB values 
in the absence of acute kernicterus, those who were too 
moribund to receive an exchange blood transfusion, or for 
whom there were no resources to perform the procedure. 
We did not include children with the subtler form of biliru-
bin-induced neurologic dysfunction, and hence the results 
presented are likely to be an underestimate of the total bur-
den of impairment following hyperbilirubinemia. In view of 
insufficient data and the likely preponderance of newborn 
female discrimination at birth and gender-selective referrals 
to tertiary care, we elected to forgo the highlighting of gen-
der differences in our model.
Data Improvement and Programmatic Implications
Coupled with promotion of maternal and newborn care, 
inclusion of essential newborn care—particularly breastfeed-
ing—and better care of preterm babies, including kangaroo 
mother care and safer management of neonatal jaundice, are 
key to public policies that engender better neonatal survival, 
improved long-term development, and reduced disability (78).
Important “know–do” gaps that need attention include the 
following:
1. Primary prevention, especially operationalizing sys-
tems strategies, including national identification of all 
Rh-negative women before or during pregnancy and 
ensuring that they receive Rh immunoprophylaxis 
postpartum and ideally at the 28th wk of pregnancy 
with coordinated obstetric and neonatal care. This will 
necessitate building partnerships with families and 
mobilizing community awareness.
2. Secondary prevention through care of affected pregnan-
cies and neonates, harnessing and implementing afford-
able and proven-effective technologies for identification 
of and improved newborn care, as being promoted by 
the Every Newborn Action Plan (79).
3. Tertiary prevention through early identification and 
care of affected survivors to address long-term medical 
and scholastic impairments among those exposed to 
severe hyperbilirubinemia.
4. Improved data and use of data, including consistent 
definitions of risk and outcomes to be measured during 
routine data collection and in special cohort studies.
Conclusions
The failure to prevent Rh sensitization and manage EHB results 
in the global burden of neonatal hyperbilirubinemia falling 
most heavily on the world’s poorest countries, especially in 
South Asia and sub-Saharan Africa. Knowledge gained to pre-
vent Rh disease 6 decades ago in high-income countries has 
not been consistently implemented. The very fact that we are 
forced to rely on data from Europe and the United States, now 
70 y old, shows the low priority given to this condition. Global 
and national leadership is needed to mobilize action and 
embed proven systems approaches, policies, and programs to 
substantially and sustainably reduce newborn deaths and dis-
ability, including jaundice-related mortality and disabilities.
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